The University of Birmingham is a red brick university located in the city of Birmingham, United Kingdom. It received its royal charter in 1900 as a successor to Queen's College, Birmingham and Mason Science College . Birmingham was the first red brick university to gain a charter. It is a founding member of both the Russell Group of British research universities and the international network of research universities, Universitas 21.The University of Birmingham was ranked 11th in the UK and 64th in the world by QS World University Rankings. In 2013, Birmingham was named 'University of the Year 2014' in the Times Higher Education awards. Birmingham is also ranked 4th in the UK for Graduate Prospects in The Times and The Sunday Times Good University Guide 2015.The student population includes around 19,000 undergraduate and 9,000 postgraduate students, which is the 11th largest in the UK. The annual income of the institution for 2010–11 was £470.7 million, with an expenditure of £443.7 million.The university is home to the Barber Institute of Fine Arts, housing works by Van Gogh, Picasso and Monet, the Lapworth Museum of Geology, the Cadbury Research Library home to the Mingana Collections of Middle Eastern manuscripts and the Chamberlain Collection, and the Joseph Chamberlain Memorial Clock Tower, which is a prominent landmark visible from many parts of the city. Academics and alumni of the university include former British Prime Ministers Neville Chamberlain, and Stanley Baldwin, and eight Nobel laureates. Wikipedia.
University of Birmingham | Date: 2017-03-08
The invention provides an agent for preventing or treating a condition characterised by the presence of unwanted cells, the agent comprising:(i) a targeting moiety that is capable of targeting to the unwanted cells; and(ii) a T cell antigen,wherein the T cell antigen can be released from the targeting moiety by selective cleavage of a cleavage site in the agent in the vicinity of the unwanted cells.
University of Birmingham | Date: 2017-01-25
Provided is a method of facilitating the determination of treatment of a subject displaying atrial fibrillation, the method comprising determining a level of pitx2c expression in a sample from the subject and selecting a treatment based upon the level of pitx2c expression. Treatment with a sodium channel blocker may be selected if the level of pitx2c expression is determined to be reduced or below a predetermined threshold. Also provided are an assay system and a kit for use in the methods of the invention.
University of Birmingham | Date: 2016-11-17
Provided is a method for treatment and/or prophylaxis of a condition associated with T cell mediated chronic inflammatory disease by administration, to a patient, of a peptide comprising N-SVTEQGAELSNEER-C (SEQ ID NO: 1) or an analogue thereof that inhibits T cell migration. Also provided is the peptide or its analogue for use in the methods of treatment and/or prophylaxis of said condition. Also provided is a method for the treatment of Sjogrens syndrome by administration of a peptide comprising N-SVTEQGAELSNEER-C to a patient in need thereof.
University of Birmingham | Date: 2017-05-31
The present invention relates to a method for identifying whether or not it may be appropriate to administer to a subject a therapy for alleviating any potential consequences which may arise due to the subject having an atrial fibrillation (AF), the method comprising detecting, in a sample of fluid from the subject, a level of ccl21 and/or ddit4 expression and determining whether or not it may be appropriate to administer to the subject a therapy for alleviating any consequences which may arise due to the subject having AF, based upon the ccl21 and/or ddit4 expression level detected. Also provided are an anticoagulant or other AF therapy and a method of administering an anticoagulant drug or another AF therapy.
University of Birmingham | Date: 2017-02-01
A method of generating at least one trapped atom of a specific species, the method comprising the steps of : positioning a sample material (18) comprising a specific species in a vacuum (14); generate an atomic vapour (20) of the specific species by irradiating the sample material with a first laser (12); trapping one or more atoms from the generated atomic vapour.
University of Birmingham | Date: 2017-03-15
The invention provides an emulsion comprising: (a) a continuous phase; (b) a dispersed phase comprising an active compound (1); and (c) colloidal particles located at the interface between the continuous phase and the dispersed phase. These are particularly useful with one or more agrochemicals or food additives as an active compound.
University of Birmingham and The Secretary Of State Of Defence Of The United Kingdom Of Great Britain And Northern Ireland | Date: 2017-01-04
The invention relates to an antimicrobial surface, in particular a surface functionalised with a peptide comprising an antimicrobial moiety. The invention comprises a surface functionalised with a peptide comprising an antimicrobial moiety and a binder moiety, wherein the peptide is immobilized on the surface by electrostatic interactions between the binder moiety and the surface. Further provided is a medical device, a peptide and a method for the immobilization of a peptide.
University of Birmingham | Date: 2017-04-05
A molecular sensor that utilises dichroism can be used toidentify the presence of specific molecules in a substance. The molecular sensor includes a sensor element comprising (i) a scaffold moiety and (ii) one or more receptor molecules for the target molecule attached to the scaffold moiety to form a scaffold/receptor complex, wherein the scaffold/receptor complexis modified to incorporate a chromophore and the modified scaffold/receptor complex has a high aspect ratio.
University of Birmingham | Date: 2017-07-12
Provided is an incretin, or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof, for use in a method of reducing elevated intracranial pressure (ICP) in a subject. Methods of reducing elevated ICP in a subject may comprise administering an incretin,or analogue thereof, an incretin receptor agonist, an incretin enhancer, or any combination thereof to the subject. The elevated ICP may be associated with idiopathic intracranial hypertension (IIH), secondary pseudotumour cerebri, hydrocephalus, normal pressure hydrocephalus, raised intracranial pressure secondary to a brain tumour, meningitis, brain trauma, brain injury, and venous sinus thrombosis.
NewSouth Innovations Pty Ltd and University of Birmingham | Date: 2017-07-12
Methods for mass production of new microfluidic devices are described. The microfluidic devices may include an array of micro-needles with open channels in fluid communication with multiple reservoirs located within a substrate that supports the micro-needles. The micro-needles are configured so as to sufficiently penetrate the skin in order to collect or sample bodily fluids and transfer the fluids to the reservoirs. The micro-needles may also deliver medicaments into or below the skin.